Evidence map›Paper›PMID 32929772›Full record

ArticleInternational journal of experimental pathology2021

Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations.

Hebah Ali, Ignazio Puccio, Ayse U Akarca, Roshanak Bob, Sabine Pomplun, Wai Keong Wong, Rajeev Gupta, Mallika Sekhar, Jonathan Lambert, Hytham Al-Masri and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of experimental pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Hebah AliHaematological Malignancy Diagnostic Service, Leeds, UK.ORCID 0000-0002-5283-8687
Ignazio PuccioDepartment of Histopathology, University College London, London, UK.
Ayse U AkarcaDepartment of Histopathology, University College London, London, UK.
Roshanak BobReference and Consultation Center for Lymphoma and Haematopathology, Pathodiagnostik Berlin, Berlin, Germany.
Sabine PomplunDepartment of Cellular Pathology, University College Hospital, London, UK.
Wai Keong WongDepartment of Haematology, University College Hospital, London, UK.
Rajeev GuptaDepartment of Haematology, University College Hospital, London, UK.
Mallika SekharDepartment of Haematology, University College Hospital, London, UK.
Jonathan LambertDepartment of Haematology, University College Hospital, London, UK.
Hytham Al-MasriHematogenix Laboratory Services, Chicago, IL, USA.
Harald SteinReference and Consultation Center for Lymphoma and Haematopathology, Pathodiagnostik Berlin, Berlin, Germany.
Teresa MarafiotiDepartment of Histopathology, University College London, London, UK.
University College Hospital · GBPathodiagnostik Berlin · DEUniversity College London · GBUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testing for the CALR mutation is included in the updated WHO criteria for essential thrombocythaemia (ET) and primary myelofibrosis (PMF). We report on the application of the CAL2 monoclonal antibody, raised against the mutated CALR gene to myeloid cases. The immunostain was used on 116 acute myeloid leukaemias (AML) and 66 myeloproliferative neoplasms (MPN) or myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN). None of AML cases was stained by the CAL2 antibody, while 20/66 MPNs and MDS/MPNs appeared positive. Fourteen of the latter cases were studied by molecular techniques, and all showed aberrations of the CALR gene. In addition, CAL2 positivity was found in some small-sized elements besides megakaryocytes. By double staining, these elements corresponded to small megakaryocytes as well as both erythroid and myeloid precursors. This finding suggests possible occurrence of CALR gene abnormalities in a stem cell.

Indexed as

Antibodies, MonoclonalCalreticulinErythrocytesGranulocytesHumansMegakaryocytesMutationMyelodysplastic-Myeloproliferative DiseasesMyeloproliferative DisordersAntibodies, MonoclonalCalreticulinCALR protein, humanCAL2CALRessential thrombocythaemiamutated calreticulinmyelofibrosismyeloproliferative neoplasms

Identifiers

PMID32929772
PMCPMC7839955
OpenAlexW3087525075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.